Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 6-12 , July 2010

The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated between 1987 and 1995

  • Howard D. Thames

      Affiliations

    • Division of Quantitative Sciences, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • Corresponding Author InformationCorresponding author. Address: Division of Quantitative Sciences Box 237, UT MD Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA.
    • ,
  • Deborah Kuban

      Affiliations

    • Division of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Larry B. Levy

      Affiliations

    • Division of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
    • ,
  • Eric M. Horwitz

      Affiliations

    • Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
    • ,
  • Patrick Kupelian

      Affiliations

    • Department of Radiation Oncology, University of California, Los Angeles, CA, USA
    • ,
  • Alvaro Martinez

      Affiliations

    • William Beaumont Hospital, Royal Oak, MI, USA
    • ,
  • Jeffrey Michalski

      Affiliations

    • Department of Radiation Oncology, Mallinckrodt Institute of Radiology, St. Louis, MO, USA
    • ,
  • Thomas Pisansky

      Affiliations

    • Division of Radiation Oncology, Mayo Medical School, Rochester, MN, USA
    • ,
  • Howard Sandler

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA
    • ,
  • William Shipley

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    • ,
  • Michael Zelefsky

      Affiliations

    • Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    • ,
  • Anthony Zietman

      Affiliations

    • Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA

Received 23 November 2009 ,Revised 15 March 2010 ,Accepted 29 March 2010.

References 

  1. Lai PP, Perez CA, Shapiro SJ, et al. Carcinoma of the prostate stage B and C: lack of influence of duration of radiotherapy on tumor control and treatment morbidity. Int J Radiat Oncol Biol Phys. 1990;19:561–568
  2. Lai PP, Pilepich MV, Krall JM, et al. The effect of overall time on the outcome of definitive radiotherapy for localized prostate carcinoma: the radiation therapy oncology group 75–06 and 77–06 experiences. Int J Radiat Oncol Biol Phys. 1991;21:925–933
  3. Amdur RJ, Parsons JT, Fitzgerald LT, et al. The effect of overall treatment time on local control in patients with adenocarcinoma of the prostate treated with radiation therapy. Int J Radiat Oncol Biol Phys. 1990;19:1377–1382
  4. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 1999;43:1095–1101
  5. Duchesne GM, Peters LJ. What is the α/β ratio for prostate cancer? Rationale for hypofractionated high-dose-rate radiotherapy. Int J Radiat Oncol Biol Phys. 1999;44:747–748
  6. Fowler J, Chappell R, Ritter M. Is α/β for prostate tumors really low?. Int J Radiat Oncol Biol Phys. 2001;50:1021–1031
  7. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 2002;52:6–13
  8. Wang Z, Guerrero M, Li XA. How low is the α/β ratio for prostate cancer?. Int J Radiat Oncol Biol Phys. 2003;55:194–203
  9. Williams SG, Taylor JMG, Liu N, et al. Use of individual fraction size data from 3756 patients to directly determine the ratio of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:24–33
  10. Haustermans KM, Hofland I, van Poppel H, et al. Cell kinetic measurements in prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37:1067–1070
  11. Miles EF, Lee WR. Hypofractionation for prostate cancer: a critical review. Sem Radiat Oncol. 2008;18:41–47
  12. D’Souza WD, Thames HD. Is the α/β ratio for prostate cancer low?. Int J Radiat Oncol Biol Phys. 2001;51:1–3
  13. Thames HD, D’Souza WD, Kuban DA. Dual radiobiological interpretations of retrospective clinical data: the time factor. Int J Radiat Biol. 2003;79:503–509
  14. d’Ambrosio DJ, Li T, Horwitz EM, Chen DYT, et al. Does treatment duration affect outcome after radiotherapy for prostate cancer?. Int J Radiat Oncol Biol Phys. 2008;72:1402–1407
  15. Roach M, Hanks G, Thames HD, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO phoenix consensus conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  16. Pollack A, Li T, Buyyounouski M, Horwitz E. Hypofractionation for prostate cancer: interim results of a randomized trial. Int J Radiat Oncol Biol Phys. 2009;75:S81
  17. Kuban DA, Thames HD, Levy LB, et al. Long-term multi-institutional analysis of stage T1–T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003;57:915–928
  18. Jereczek-Fossa BA, Orecchia R. Evidence-based radiation oncology: definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radiother Oncol. 2007;84:197–215
  19. Brahme A. Dosimetric precision requirements in radiation therapy. Acta Oncol. 1984;23:379–391
  20. Bentzen SM, Joiner MC. The linear-quadratic approach in clinical practice. In:  Joiner MC,  van der Kogel AJ editor. Basic clinical radiobiology. 4th ed.. London: Arnold; 2009;p. 120–134
  21. Bentzen SM, Ritter MA. The α/β ratio for prostate cancer: what is it, really?. Radiother Oncol. 2005;76:1–3
  22. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–146
  23. Roberts SA, Hendry JH, Brewster AE, Slevin NJ. The influence of radiotherapy treatment time on the control of laryngeal cancer: a direct analysis of data from two British Institute of Radiology trials to calculate the lag period and the time factor. Br J Radiol. 1994;67:790–794
  24. Withers HR, Peters LJ, Taylor JM, et al. Local control of carcinoma of the tonsil by radiation therapy: an analysis of patterns of fractionation in nine institutions. Int J Radiat Oncol Biol Phys. 1995;33:549–562
  25. Hendry JH, Bentzen SM, Dale RG, et al. A modelled comparison of the effects of using different ways to compensate for missed treatment days in radiotherapy. Clin Oncol. 1996;8:297–307
  26. Koukourakis M, Hlouverakis G, Kosma L, et al. The impact of overall time on the results of radiotherapy for nonsmall cell lung carcinoma. Int J Radiat Oncol Biol Phys. 1996;34:315–322
  27. Robertson C, Robertson AG, Hendry JH, et al. Similar decreases in local tumor control are calculated for treatment protraction and for interruptions in the radiotherapy of carcinoma of the larynx in four centers. Int J Radiat Oncol Biol Phys. 1998;40:319–329
  28. Hinata H, Inakoshi H, Sakai K, et al. Estimation of time parameter of LQ-model in fractionated radiotherapy of medulloblastoma. Radiat Med. 2001;19:61–70
  29. Geh JI, Bond SJ, Bentzen SM, Glynne-Jones R. Systematic overview of preoperative (neoadjuvant) chemoradiotherapy trials in oesophageal cancer: evidence of a radiation and chemotherapy dose response. Radiother Oncol. 2006;78:236–244
  30. Valdagni R, Italia C, Montanaro P, Lanceni A, Lattuada P, Magnani T, et al. Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy. Radiother Oncol. 2005;75:74–82

PII: S0167-8140(10)00205-7

doi: 10.1016/j.radonc.2010.03.020

Radiotherapy & Oncology
Volume 96, Issue 1 , Pages 6-12 , July 2010

Article Tools

* Image Usage & Resolution